Optinose is a specialty pharmaceutical company focused on the development and commercialization of products for patients cared for by, or in consultation with, ear, nose, and throat (ENT) or allergy specialists.
We are focused on value creation, starting with our work on a unique and novel drug delivery concept known as Bi-Directional™ Exhalation Delivery Systems. The innovative mechanism of action of the first Optinose technology is designed to enable broad, consistent drug delivery high and deep in the nasal passages, leveraging the mucosal surfaces as a potential target for the treatment of both local and systemic diseases.
As of September 2017, two products utilizing an Exhalation Delivery System have been approved by the FDA, and we have a robust pipeline of candidates in various phases of clinical trials.
US Headquarters Address
1020 Stony Hill Road, Suite 300
Yardley, PA 19067